Abstract:Purpose Glucophage R (Merck Healthcare KGaA, Darmstadt, Germany) is the originator brand of metformin hydrochloride, an oral antidiabetic drug. Metformin is recommended in guidelines as first-line treatment of type 2 diabetes mellitus and increasingly in related insulin-resistant conditions, such as prediabetes and polycystic ovary syndrome. The GelShield R sustained-release formulation tablet of Glucophage R has been improved from the historic version marketed in 2000. Bioequivalence has been demonstrated stepwise along this evolution; however, a head-to-head evaluation between the initial and the current version is missing. This analysis aims to close this gap and to determine bioequivalence between related originator GelShield R sustained-release formulations of metformin, Glucophage R (GXR 500 mg), from Europe and the United States. Methods Data from seven randomized crossover bioequivalence studies in 361 healthy participants of Asian and non-Asian ethnicity from Europe, the United States, and Asia were considered. All evaluated a single oral dose of 500 mg of the test and reference formulation in healthy male and female participants in fed and fasted state. Bioequivalence was evaluated by means of a combined bridging analysis of available data on the current round tablet from Europe (rGXR EU) and the historic oblong tablet from the United States (oGXR US) in healthy Asian and non-Asian participants under fed and fasting conditions. Bioequivalence between the two formulations was assessed statistically with a mixed effects model for AUC 0-t , C max , and AUC 0-inf . Findings In all studies, bioequivalence between the respective test and reference formulations of GXR was shown. Statistical analysis of pooled pharmacokinetic data of 2 (primary pooling set) or 3 studies (secondary pooling set) demonstrated bioequivalence between rGXR EU and oGXR US via bridging with oGXR EU. The 90% CI for the geometric mean ratio of all pharmacokinetic parameters was within the bioequivalence range of 0.80 to 1.25. In the primary pooling set, geometric least squares mean ratios in the fed group ranged from 0.9931 (90% CI, 0.9151–1.0778) for AUC 0-inf to 1.1344 (90% CI, 1.0711–1.2014) for C max ; results in the fasted group were similar. The secondary pooling set, which added a study in Asians, confirmed these findings. Implications Bioequivalence was determined between sustained-release formulations of Glucophage R from Europe and the United States under fasted and fed conditions in healthy men and women, including different ethnicities. The efficacy and safety of Glucophage R XR can be claimed along the evolution from oGXR US, via oGXR EU to rGXR EU, and in several ethnicities and production sites.

Pharmacokinetics and Comparative Bioavailability of Two Metformin Formulations after Single-Dose Administration in Healthy Subjects

Pharmacokinetics and Relative Bioavailability of Metformin Extended-release Tablets in Healthy Volunteers

Bioequivalence and Pharmacokinetic Evaluation of Two Metformin Hydrochloride Tablets Under Fasting and Fed Conditions in Healthy Chinese Volunteers

Study of bioequivalence of compound metformin hydrochloride tablet in healthy volunteers

Pharmacokinetic and Bioequivalence Studies of 2 Metformin Glibenclamide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions

Study on the relative bioavailability of metformin hydrochloride sustained-release tablets

Relative bioavailability of compound metformin hydrochloride tablets in healthy volunteers

Pharmacokinetics and relative bioavailability of compound metformin hydrochloride tablet in healthy volunteers

Bioequivalence of Two Domestic Praperations of Metformin Hydrochloride Entericcoated Capsules in Chinese Healthy Volunteers

Study on bioequivalence of cilostazol table in healthy volunteers

Relative Bioavailability and Bioequivalence of Metforphin Hydrochloride Extended-Released and Immediate-Released Tablets in Healthy Chinese Volunteers

Pharmacokinetics of glibenclamide/metformin hydrochloride combination

Bioavailability Evaluation of Sustained-Release Metformin Formulation after Single and Multiple Oral Dosing in Healthy Volunteers

Pharmacokinetics and Bioequivalence of Compound Mefformin Hydrochloride Tablets in Healthy Volunteers

Bioequivalence and Safety Assessment of 2 Formulations of Low‐Dose Metformin Hydrochloride under Fasting Conditions in Healthy Chinese Participants: A Randomized Phase I Clinical Trial

Pharmacokinetics and bioequivalance of domestic compound glibenclamide and metformin in chinese healthy volunteers

Pharmacokinetic comparison of sitagliptin and metformin HCl extended-release tablets versus JANUMET® XR in healthy volunteers under fasting and fed conditions

Bioequivalence of Related GelShield R Sustained-Release Formulations of Metformin: A Pooled Pharmacokinetic Analysis

Comparative Bioavailability of Metformin Hydrochloride Oral Solution Versus Metformin Hydrochloride Tablets in Fasting Mexican Healthy Volunteers

Bioequivalence and Safety Assessment of Two Formulations of Metformin Hydrochloride Sustained-Release Tablets (Yuantang® SR and Glucophage® XR) Under Fed Conditions in Healthy Chinese Adult Subjects: An Open-Label, Two-Way Crossover, Sequence Randomized Phase I Clinical Trial

Post-Marketing Reevaluation of Bioequivalénce of Metformin Hydrochloride Enteric-Coated Tablets